220 related articles for article (PubMed ID: 32193825)
1. Utility of GATA-3 Expression in the Analysis of Pituitary Neuroendocrine Tumour (PitNET) Transcription Factors.
Turchini J; Sioson L; Clarkson A; Sheen A; Gill AJ
Endocr Pathol; 2020 Jun; 31(2):150-155. PubMed ID: 32193825
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours.
Turchini J; Sioson L; Clarkson A; Sheen A; Gill AJ
Endocr Pathol; 2021 Sep; 32(3):408-414. PubMed ID: 33694064
[TBL] [Abstract][Full Text] [Related]
3. A clinicopathological study of non-functioning pituitary neuroendocrine tumours using the World Health Organization 2022 classification.
Woo CS; Ho RS; Ho G; Lau HT; Fong CH; Chang JY; Leung EK; Tang LC; Ma IK; Lee AC; Lui DT; Woo YC; Chow WS; Leung GK; Tan KC; Lam KS; Lee CH
Front Endocrinol (Lausanne); 2024; 15():1368944. PubMed ID: 38756997
[TBL] [Abstract][Full Text] [Related]
4. GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors.
Mete O; Kefeli M; Çalışkan S; Asa SL
Mod Pathol; 2019 Apr; 32(4):484-489. PubMed ID: 30390035
[TBL] [Abstract][Full Text] [Related]
5. Unveiling the identities of null cell tumours: Epigenomics corroborate subtle histological cues in pituitary neuroendocrine tumour/adenoma classification.
Dottermusch M; Schüller U; Hagel C; Saeger W
Neuropathol Appl Neurobiol; 2023 Feb; 49(1):e12870. PubMed ID: 36527335
[TBL] [Abstract][Full Text] [Related]
6. A specific antibody to detect transcription factor T-Pit: a reliable marker of corticotroph cell differentiation and a tool to improve the classification of pituitary neuroendocrine tumours.
Sjöstedt E; Bollerslev J; Mulder J; Lindskog C; Pontén F; Casar-Borota O
Acta Neuropathol; 2017 Oct; 134(4):675-677. PubMed ID: 28823042
[No Abstract] [Full Text] [Related]
7. The Role of T-box Transcription Factor in a Pituitary Adenoma Diagnostic Algorithm.
McDonald WC; McDonald KN; Helmer JA; Ho B; Wang A; Banerji N
Arch Pathol Lab Med; 2021 May; 145(5):592-598. PubMed ID: 32991684
[TBL] [Abstract][Full Text] [Related]
8. The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas.
Nishioka H; Inoshita N; Mete O; Asa SL; Hayashi K; Takeshita A; Fukuhara N; Yamaguchi-Okada M; Takeuchi Y; Yamada S
Endocr Pathol; 2015 Dec; 26(4):349-55. PubMed ID: 26481628
[TBL] [Abstract][Full Text] [Related]
9. Steroidogenic Factor 1, Pit-1, and Adrenocorticotropic Hormone: A Rational Starting Place for the Immunohistochemical Characterization of Pituitary Adenoma.
McDonald WC; Banerji N; McDonald KN; Ho B; Macias V; Kajdacsy-Balla A
Arch Pathol Lab Med; 2017 Jan; 141(1):104-112. PubMed ID: 27227698
[TBL] [Abstract][Full Text] [Related]
10. Cytokeratin 8/18-negative somatotroph pituitary neuroendocrine tumours (PitNETs, adenomas) show variable morphological features and do not represent a clinicopathologically distinct entity.
Soukup J; Cesak T; Hornychova H; Manethova M; Michnova L; Netuka D; Vitovcova B; Cap J; Ryska A; Gabalec F
Histopathology; 2021 Sep; 79(3):406-415. PubMed ID: 33738859
[TBL] [Abstract][Full Text] [Related]
11. Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1.
Asa SL; Mete O; Riddle ND; Perry A
Endocr Pathol; 2023 Sep; 34(3):273-278. PubMed ID: 37268858
[TBL] [Abstract][Full Text] [Related]
12. Proposal of a clinically relevant working classification of pituitary neuroendocrine tumors based on pituitary transcription factors.
Silva-Ortega S; García-Martinez A; Niveiro de Jaime M; Torregrosa ME; Abarca J; Monjas I; Picó Alfonso A; Aranda López I
Hum Pathol; 2021 Apr; 110():20-30. PubMed ID: 33321163
[TBL] [Abstract][Full Text] [Related]
13. A review of multiomics platforms in pituitary adenoma pathogenesis.
Mouchtouris N; Smit RD; Piper K; Prashant G; Evans JJ; Karsy M
Front Biosci (Landmark Ed); 2022 Mar; 27(3):77. PubMed ID: 35345309
[TBL] [Abstract][Full Text] [Related]
14. Structure, Function, and Morphology in the Classification of Pituitary Neuroendocrine Tumors: the Importance of Routine Analysis of Pituitary Transcription Factors.
Mete O; Asa SL
Endocr Pathol; 2020 Dec; 31(4):330-336. PubMed ID: 32813227
[TBL] [Abstract][Full Text] [Related]
15. Utility of Pit-1 Immunostaining in Distinguishing Pituitary Adenomas of Primitive Differentiation from Null Cell Adenomas.
Lee JC; Pekmezci M; Lavezo JL; Vogel H; Katznelson L; Fraenkel M; Harsh G; Dulai M; Perry A; Tihan T
Endocr Pathol; 2017 Dec; 28(4):287-292. PubMed ID: 28994039
[TBL] [Abstract][Full Text] [Related]
16. Reverse transcription polymerase chain reaction analysis of pituitary hormone, Pit-1 and steroidogenic factor-1 messenger RNA expression in pituitary tumors.
McDermott MT; Haugen BR; Gordon DF; Wood WM; Brown NS; Bauer CA; Garrity MJ; Kleinschmidt-DeMasters BK; Lillehei KO; Samuels MH; Bright TM; Ridgway EC
Pituitary; 1999 Nov; 2(3):217-24. PubMed ID: 11081157
[TBL] [Abstract][Full Text] [Related]
17. Expression of kisspeptin and KISS1 receptor in pituitary neuroendocrine tumours - an immunohistochemical study.
Mihajlovic M; Pekic S; Doknic M; Stojanovic M; Miljic D; Soldatovic I; Vukotic T; Janev T; Cirovic S; Terzic T; Raicevic S; Skender-Gazibara M; Popovic V; Manojlovic-Gacic E
Endokrynol Pol; 2021; 72(2):91-96. PubMed ID: 33619706
[TBL] [Abstract][Full Text] [Related]
18. Overview of the 2022 WHO Classification of Pituitary Tumors.
Asa SL; Mete O; Perry A; Osamura RY
Endocr Pathol; 2022 Mar; 33(1):6-26. PubMed ID: 35291028
[TBL] [Abstract][Full Text] [Related]
19. [WHO Histological Classification of Pituitary Tumors].
Nishioka H
No Shinkei Geka; 2023 Jul; 51(4):642-653. PubMed ID: 37491061
[TBL] [Abstract][Full Text] [Related]
20. Double adenomas of the pituitary: transcription factors Pit-1, T-pit, and SF-1 identify cytogenesis and differentiation.
Jastania RA; Alsaad KO; Al-Shraim M; Kovacs K; Asa SL
Endocr Pathol; 2005; 16(3):187-94. PubMed ID: 16299401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
